ArticlePharmaceutical nanotechnology2025
Green Synthesis of Silver Nanoparticles from
Article in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimNanotechnology is considered as one of the fastest-developing areas in the biomedicine field. Hence, the green synthesis of silver nanoparticles from Syzygium cumini seed extract was carried out in this study.
methodsThe synthesized nanoparticles were characterized by UV-Vis spectroscopy, FTIR (Fourier transform infrared), FE-SEM (Field Emission scanning electron microscope), AFM (Atomic Force Microscope), XRD (X-ray diffraction), and EDX (Energy dispersive X-Ray). Their antioxidant and anti-inflammatory activity were evaluated by DPPH (2,2-diphenyl-1-picrylhydrazyl), PM (Phosphomolybdenum) assay, and albumin denaturation assay. Further, the antibacterial activity of the nanoparticles was studied against Gram-positive and Gram-negative bacteria using the agar well diffusion method. In addition, the antidiabetic activity of nanoparticles was studied by α-amylase and α-glucosidase inhibition assays.
resultsThe surface plasmon resonance at 430 nm confirmed the formation of silver nanoparticles. They were stable and spherical in shape, with sizes ranging from 30 to 90 nm. The DPPH inhibition % of silver nanoparticles varied from 7.91±0.39% to 68.35±0.76%. The % inhibition of albumin denaturation was comparable to the diclofenac. Further, the results of antibacterial activity revealed that the zone of inhibition for all the test bacteria varied from 14.33±0.58 to 25.33±0.58 mm, where B. cereus was more susceptible. In addition, the % inhibition of α-amylase and α-glucosidase varied from 19.91±0.15% to 61.43±0.31% and 15.26±0.11% to 55.38±0.20%, respectively.
conclusionThis study is the first attempt of utilizing the silver nanoparticles synthesized from S. cumini seed extract for antidiabetic activity. The study suggests that these nanoparticles could be well utilized in pharmaceutical industries as an efficient antioxidant, anti-inflammatory, antibacterial, and antidiabetic drug.
Indexed as
Identifiers
39092639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.